Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

EHA 2019

Videos
News
Chemotherapy-free strategies in treating leukaemia
Prof Robin Foa - University of Rome, Rome, Italy
Chemotherapy-free strategies in treating leukaemia ( Prof Robin Foa - University of Rome, Rome, Italy )
20 Jun 2019
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph...
Prof Robin Foa - University of Rome, Rome, Italy
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients ( Prof Robin Foa - University of Rome, Rome, Italy )
20 Jun 2019
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL
Prof Max Topp - University of Würzburg, Würzburg, Germany
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
20 Jun 2019
ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients...
Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA
ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )
20 Jun 2019
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...
Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
20 Jun 2019
Multiple myeloma science from EHA 2019
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Multiple myeloma science from EHA 2019 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
20 Jun 2019
CAR T-cell therapy for treating acute leukaemia
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
CAR T-cell therapy for treating acute leukaemia ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
20 Jun 2019
Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory...
Prof Walter Fiedler - University of Hamburg, Hamburg, Germany
Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia ( Prof Walter Fiedler - University of Hamburg, Hamburg, Germany )
20 Jun 2019
Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy...
Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China
Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM ( Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China )
20 Jun 2019
ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy...
Dr Andrea Gallamini - Centre Antoine Lacassagne, Nice, France
ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma ( Dr Andrea Gallamini - Centre Antoine Lacassagne, Nice, France )
20 Jun 2019
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low...
Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
20 Jun 2019
PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin...
Michael Fuchs - University Hospital of Cologne, Cologne, Germany
PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma ( Michael Fuchs - University Hospital of Cologne, Cologne, Germany )
20 Jun 2019
HORIZON update: Using melflufen to treat RRMM patients refractory to...
Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
20 Jun 2019
Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients...
Dr Mark Roschewski - National Cancer Institute, Bethesda, USA
Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )
20 Jun 2019
Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia
Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA
Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia ( Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA )
20 Jun 2019
CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )
20 Jun 2019
Chemoimmunotherapy or BTK inhibition for patients with CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )
20 Jun 2019
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Blinatumomab for relapsed/refractory Burkitt's lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
Blinatumomab for relapsed/refractory Burkitt's lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Using bioinformatics and genomics to treat AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019
The changing landscape of AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019
CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL
Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany
CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL ( Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany )
20 Jun 2019
RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first...
Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano...
RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first-line treatment ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )
19 Jun 2019
CD33 T cell recruiting antibody constructs for treatment of relapsed refractory...
Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany
CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )
19 Jun 2019
Targeted treatment of AML using T cell recruiting antibody constructs
Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany
Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )
19 Jun 2019
Use of maintenance therapy following ASCT and real world treatment patterns in...
Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold
Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma ( Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold )
15 Jun 2019
Myeloma highlights from EHA 2019
Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain
Myeloma highlights from EHA 2019 ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )
15 Jun 2019
Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia
Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands
Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )
15 Jun 2019
Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and...
Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands
Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )
15 Jun 2019
AlloHCT conditioning intensity in AML in complete remission with residual...
Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda...
AlloHCT conditioning intensity in AML in complete remission with residual disease ( Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA )
15 Jun 2019
ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
15 Jun 2019
Inhibition of NADK strongly inhibits T-ALL cells from growing
Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK
Inhibition of NADK strongly inhibits T-ALL cells from growing ( Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK )
15 Jun 2019
Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable...
Dr Mark Roschewski - National Cancer Institute, Bethesda, USA
Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )
15 Jun 2019
Acalabrutinib monotherapy shows significant benefit in relapsed or refractory...
Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia ( Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
15 Jun 2019
Venetoclax with bortezomib and dexamethasone shows good response but higher...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
15 Jun 2019
Imetelstat provides durable transfusion independence in heavily transfused non...
Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France
Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS ( Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France )
14 Jun 2019
D-VTd in induction prior to and consolidation after ASCT improves PFS and depth...
Prof Philippe Moreau - Chu Nantes, Nantes, France
D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety ( Prof Philippe Moreau - Chu Nantes, Nantes, France )
14 Jun 2019
Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305...
Dr Ekaterina Chelysheva - National Research Center for Hematology, Moscow...
Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry ( Dr Ekaterina Chelysheva - National Research Center for Hematology, Moscow, Russian Federation )
14 Jun 2019
Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with...
Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany
Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities ( Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany )
14 Jun 2019
Intervention for AML patients with MRD can result in improved survival
Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart...
Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )
14 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation